// App-Quantinova.ai

7595 : A randomized, multicenter phase III study of lobaplatin/etoposide versus cisplatin/etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer and circulating tumor cells (CTCs) as an exploratory biomarker.

Researchers

Presenter

  • Ying Cheng

Principal Investigators

  • Yun Fan

  • Xiaoqing Liu

  • Jun Liang

  • Jianhua Shi

  • Dong Wang

  • Yan Yu

  • Shukui Qin

  • Wei Liu

  • Cheng Huang

  • Helong Zhang

  • Lijun Sheng

  • Yunpeng Liu

  • Jiwei Liu

Medical Centers

  • 307 Hospital of the Academy of Military Medical Sciences, Cancer Center, Beijing, China

  • Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China

  • Fujian Provincial Tumor Hospital, Fuzhou, China

  • The Affiliated Hospital of Qingdao University, Qingdao, China

  • Third Affiliated Hospital Third Military Medical University of Peoples Liberation Army, Chongqing, China

  • PLA Cancer Center of Nanjing Bayi Hospital, Nanjing, ChinaTangdu Hospital, 4th Military Medical University, Xian, ChinaCancer Hospital of Harbin Medical University, Harbin, China

  • Shandong Cancer Hospital, Jinan, China

  • Hebei Tumor Hospital, Shijiazhuang, China

  • Zhejiang Cancer Hospital, Hangzhou, China

  • Second Affiliated Hospital of Dalian Medical University, Dalian, China

  • Linyi Cancer Hospital, Linyi, China

  • Jilin Provincial Cancer Hospital, Changchun, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Small cell lung cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • lobaplatin

  • Etoposide

  • Etoposide phosphate

  • Cisplatin

Outcome

  • Positive

Study Design

  • randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved